Dear EllenFitz: The rationale for doing AC+T sequentially is toxicity, especially in the dose-dense setting. Early trials have suggested that there may be advantange to doing dose-dense therapy over the every three week schedule. There is no advantage to
neulastaNeulasta over neupogen. However, due to the duration of neulasta, neupogen may be preferred in the dose-dense setting. The only other potential difference is cost. Neupogen may be a little less expensive.